Search

Accurate conversion of neutron time-of-flight (TOF) to wavelength is of fundamental importance to neutron scattering measurements in order to ensure the accuracy of the instruments and the experimental results. Equally important in these measurements is the determination of uncertainties, and with the appropriate precision. Especially in cases where instruments are highly configurable, the determination of the absolute wavelength after any change must always be performed (e.g. change of detector position). Inspired by the manner with which neutron spectrometers determine the absolute wavelength, we evaluate for the first time, in the author's knowledge, a commonly used method for converting TOF to neutron wavelength by measuring the neutron flight path length from the source of neutrons to a monitor and we proceed to analytically calculate the uncertainty contributions that limit the precision of the conversion. The method was evaluated at the V20 test beamline at the Helmholtz Zentrum Berlin (HZB), emulating the ESS source with a long pulse of 2.86 ms length and 14 Hz repetition rate, by using a mini-chopper operated at 140 Hz and two portable beam monitors (BMs), as well as accompanied data acquisition infrastructure. The mini-chopper created well-defined neutron pulses and the BM was placed at two positions, enabling the average wavelength of each of the pulses created to be determined. The used experimental setup resulted in absolute wavelength determination at the monitor positions with a δλ mean / λ mean of ∼1.8% for λ > 4 Å. With the use of a thinner monitor, a δλ mean / λ mean of ∼1% can be reached and with a modest increase of the distance between the reference monitor positions a δλ mean / λ mean of below 0.5% can be achieved. Further improvements are possible by using smaller chopper disc openings and a higher rotational speed chopper. The method requires only two neutron measurements and doesn't necessitate the use of crystals or complex fitting with sigmoid functions and multiple free variables, and could constitute a suitable addition to imaging, diffraction, reflectometers and small angle neutron scattering instruments, at spallation sources, that do not normally utilise fast choppers.

Beamline I22 at Diamond Light Source is dedicated to the study of soft matter systems from both biological and materials science. The beamline can operate in the range 3.7 keV to 22 keV for transmission SAXS and 14 keV to 20 keV for microfocus SAXS with beamsizes 240 x 60 {\mu}m$^{2}$ spot [Full width half maximum (FWHM) Horizontal (H) x Vertical (V)] at sample for the main beamline, and approximately 10 x 10 {\mu}m$^{2}$ for the dedicated microfocussing platform. There is a versatile sample platform for accommodating a range of facility, and user developed, sample environments. The high brilliance of the insertion device source on I22 allows structural investigation of materials under extreme environments (for example fluid flow at high pressures and temperatures). I22 provides reliable access to millisecond timescales, essential to understanding kinetic processes such as early folding events in proteins or structural evolution in polymers and colloids., Comment: Preprint. 27 pages, 5 figures. Supplementary Info. 8 pages, 7 figures

The performance of dosage guidelines for starting gentamicin therapy was evaluated prospectively in 50 patients with suspected or proven Gram-negative septicaemia and the results were compared with results from similar group of 50 patients for whom the guidelines were not followed. Peak concentrations were significantly higher when the guidelines were followed (7.2 (+/- 1.9) mg/L vs 5.7 (+/- 1.8) mg/L) but there was no difference in trough concentrations. Fifty-eight per cent of patients had both peak and trough concentrations within the target range (peak > 5 mg/L, trough 7 mg/L in only 56% of patients. A revised protocol with higher doses given less frequently was therefore developed and a prospective assessment of its performance indicated that satisfactory concentrations were obtained in 96% of patients.